BioCryst Pharmaceuticals, Inc. (BCRX) ended last trading session with a change of -3.15 percent. It trades at an average volume of 1.75M shares versus 2.36M shares recorded at the end of last trading session. The share price of $8.6 is at a distance of 264.41 percent from its 52-week low and down -5.49 percent versus its peak. The company has a market cap of $634.38M and currently has 73.77M shares outstanding. The share price is currently 27.45 percent versus its SMA20, 33.84 percent versus its SMA50, and 77.78 percent versus its SMA200. The stock has a weekly performance of 10.26 percent and is 35.86 percent year-to-date as of the recent close.
On Feb. 27, 2017 BioCryst Pharmaceuticals, Inc. (BCRX) announced financial results for the fourth quarter and full year ended December 31, 2016. In a separate press release issued earlier, BioCryst announced positive results from an interim analysis of its APeX-1 clinical trial of BCX7353 for the treatment of HAE attacks.
Fourth Quarter Financial Results
For the three months ended December 31, 2016, total revenues increased to $9.0 million from $4.6 million in the fourth quarter of 2015. This increase, compared to the fourth quarter of 2015, resulted from higher peramivir royalty revenue and inventory sales to Seqirus, and was slightly offset by lower collaborative revenue in the fourth quarter of 2016.
ImmunoGen, Inc. (IMGN) recently recorded 2.41 percent change and currently at $3.82 is 152.98 percent away from its 52-week low and down -60.94 percent versus its peak. It has a past 5-day performance of 13.69 percent and trades at an average volume of 2.28M shares. The stock has a 1-month performance of 55.28 percent and is 87.25 percent year-to-date as of the recent close. There were about 85.71M shares outstanding which made its market cap $327.41M. The share price is currently 28.27 percent versus its SMA20, 46.69 percent versus its SMA50, and 38.41 percent versus its SMA200.
On March 2, 2017 ImmunoGen, Inc. (IMGN) announced that nine abstracts highlighting the breadth of the Company’s expertise in ADCs will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting to be held from April 1-5, 2017 in Washington D.C. The presentations at AACR cover a wide array of ADC innovations, including further advancements to linkers and payloads and novel targets for both solid tumors and hematological malignancies.